EMBO Molecular Medicine is an open access journal in the field of experimental medicine, dedicated to science at the interface between clinical research and basic life sciences. In addition to human data, we welcome original studies performed in cells and/or animals provided they demonstrate human disease relevance.

To enhance and better specify our commitment to precision medicine, we have expanded the scope of EMM and call for contributions in the following fields:

Environmental health and medicine, in particular studies in the field of environmental medicine in its functional and mechanistic aspects (exposome studies, toxicology, biomarkers, modeling, and intervention).
Clinical studies and case reports - Human clinical studies providing decisive clues how to control a given disease (epidemiological, pathophysiological, therapeutic, and vaccine studies). Case reports supporting hypothesis-driven research on the disease.
Biomedical technologies - Studies that present innovative materials, tools, devices, and technologies with direct translational potential and applicability (imaging technologies, drug delivery systems, tissue engineering, and AI)

Philippe Sansonetti (Chief Editor) 
(Institut Pasteur, Paris)
 
Philippe Sansonetti trained as a medical doctor at the Université Paris VI, France before moving into research. In 1989 he founded and became the director of the Insitut Pasteur’s Molecular Microbial Pathogenesis Unit. He is Professor of Microbiology and Infectious Diseases at the Collège de France. He has acted as Medical Director of the Institut Pasteur hospital, and held administrative positions at INSERM, the French Ministry of Research and Technology and the World Health Organisation.
 
Sansonetti’s research focuses on the molecular pathogenesis of bacterial infections. He has contributed detailed understanding of the molecular mechanisms through which Shigella invades and kills cells, and is developing vaccine candidates against this dysentery-causing bacterium.
 
His work has been recognized by numerous awards and he is an elected member of national and international organisations, including EMBO, the French Academy of Sciences, The Royal Society and the US National Academy of Sciences.
 
editor@embomolmed.org
 
       Céline Carret (Senior Scientific Editor)
Responsible for: neuroscience, genetic disease, mitochondrial diseases, myopathies, stem cells, regenerative medicine, gene therapy, host-pathogen interactions, innate immunity and vaccinology, aging, skin disorders
 
Céline Carret completed her PhD at the University of Montpellier, France, characterising host immunodominant antigens to fight babesiosis, a parasitic disease caused by a unicellular Apicomplexan parasite closely related to the malaria agent Plasmodium. She further developed her post-doctoral career on malaria working at the Wellcome Trust Sanger Institute in Cambridge, UK and Instituto de Medicina Molecular in Lisbon, Portugal. Céline joined EMBO Molecular Medicine as a Scientific Editor in March 2011.
/pb-assets/embo-site/images/headshots/
c.carret@embomolmed.org
tel: +49 6221 8891 411
 
       Lise Roth (Scientific Editor)
Responsible for: cancer, cancer stem cells, immunotherapy, immune disorders, metabolism, obesity and diabetes, angiogenesis, cardiovascular diseases, respiratory diseases, asthma
 
Lise Roth received her PhD in 2008 from the University of Strasbourg, France, where she studied the role of the transmembrane domain of NRP1 in Sema3A and VEGF signaling. She carried out post-doctoral research on tumor-targeting peptides in Sanford Burnham Prebys Medical Discovery Institute, Santa Barbara, USA, and in 2011, joined the German Cancer Research Center (DKFZ), where she focused on NRP1-mediated vascular permeability and on the role of Tie1 in tumor angiogenesis and metastasis. Lise joined EMBO Molecular Medicine as a Scientific Editor in January 2018.
 
l.roth@embomolmed.org
tel: +49 6221 8891 412
 
       Jingyi Hou (Scientific Editor)
Responsible for: biomarkers and diagnostics, genomics, proteomics, metabolomics, and systems medicine
 
Jingyi Hou received her PhD from the Free University Berlin / Max-Delbrück Center for Molecular Medicine, where she dissected cis-regulatory mechanisms that control mRNA translation using various mouse models. As a post-doc, she joined the laboratory of Erin O’Shea at the HHMI - Janelia Research Campus in USA, where she focused on the role of RNA methylation in the nervous system development and in learning and memory formation. Jingyi joined EMBO Molecular Medicine as a Scientific Editor in November 2018.
 
j.hou@embomolmed.org
tel: +49 6221 8891 116
 
JOURNAL STAFF
From left: Annika Diederich (Editorial Assistant), Christopher Rickerby (Editorial Assistant), Erica Wilfong Boxheimer (Data Integrity Analyst), Fiona Panayi (Editorial Administrator), Joel Maupin (Marketing and Project Manager)
 
 
 
WILEY EDITORIAL STAFF
Cate Livingstone   - Executive Editor, Global Research, Wiley
Georgi Hristov      - Assistant Editor, EMBO Press
Vivian Killet    - Assistant Editor, EMBO Press
Uta Mackensen     - Graphics Editor
SENIOR EDITORS
       Dario Alessi (MRC, Dundee)
 
d.r.alessi@dundee.ac.uk
 
Dario Alessi discovered PDK1, a master regulator of insulin-controlled responses and a key anti-cancer agent. His group has also identified a key activatory link between LKB1 and AMPK that impacts on LKB1's activity as tumour-suppressor and as activator for a number of other genes, some of which have been associated with Alzheimer's disease.
       Giulio Cossu (Institute of Inflammation and Repair, University of Manchester, Manchester)
 
giulio.cossu@manchester.ac.uk
 
Giulio Cossu's interests are in the pathophysiology of muscle development. His group has been working for a number of years on the signals and mechanism that regulate the formation of skeletal muscle during embryonic development and, after birth, when the muscle tissue is damaged as a result of an injury or a primary myopathy.
       Stefanie Dimmeler (Goethe University, Frankfurt)
 
dimmeler@em.uni-frankfurt.de
 
Stefanie Dimmeler is Professor of Experimental Medicine and Director of the Institute of Cardiovascular Regeneration, Center for Molecular Medicine at the University of Frankfurt, Germany. Her group elucidates the basic mechanisms underlying cardiovascular disease and vessel growth with the aim to develop new cellular and pharmacological therapies for improving the treatment of cardiovascular disease. Her current ongoing research focuses on epigenetic mechanisms that control cardiovascular repair, specifically the function of histone modifying enzymes and microRNAs. She received several international prizes including the Leibniz Award 2005, the Award of the Jung Foundation 2007 and the FEBS award in 2006.
       Uta Francke (Stanford School of Medicine, Stanford)
 
ufrancke@stanford.edu
 
Uta Francke's research interests are to understand the functional consequences of microdeletions that cause defined clinical syndromes. Her laboratory has created mouse models for Williams-Beuren syndrome and Prader-Willi syndrome (PWS). The PWS mice are deleted for an imprinted cluster of C/D box small nucleolar RNA (snoRNA) genes. Current goals are to identify the function of these snoRNAs and to understand how their loss causes the PWS phenotype. 
       Fred Gage (Salk Institute, San Diego)
 
gage@salk.edu
 
Fred Gage concentrates on the adult central nervous system and the plasticity and adaptability to environmental stimulation that remains throughout the life of all mammals. His work may open up the possibility for replacement of brain tissue lost to stroke or Alzheimer's disease and repairing spinal cords damaged by trauma.
       Matthias Hentze (EMBL, Heidelberg)
 
hentze@embl.de
 
Matthias Hentze's main research interests are the regulation of translation by RNA-binding proteins and microRNAs and the impact that errors in RNA processing and translation have on the ontogeny, progression, diagnosis and therapeutics of human disease. Matthias Hentze is a strong proponent of the concept of "from bench to bedside - and back".
       Gökhan S. Hotamışlıgil (Harvard University School of Public Health, Boston)
 
ghotamis@hsph.harvard.edu
 
Gökhan Hotamışlıgil is the James S. Simmons Professor of Genetics & Metabolism and Chair of the Department of Genetics & Complex Diseases at the Harvard University School of Public Health. His research centres on the molecular mechanisms of integration between nutrient and pathogen sensing and response pathways in metabolic homeostasis, the metabolic functions of the endoplasmic reticulum, and molecules that govern the biological functions of lipids. Gökhan Hotamışlıgil's contributions have led to the emerging field of "immunometabolism" and produced novel translational avenues against chronic metabolic diseases.
       Joan Massagué (Memorial Sloan-Kettering Cancer Center, New York)
 
j-massague@ski.mskcc.org
 
Joan Massagué received his Ph.D. degree from the University of Barcelona. He then joined the faculty at the University of Massachusetts Medical School and was later appointed Chair of Cancer Biology, Memorial Sloan-Kettering Cancer Center. He is currently Director of the Sloan-Kettering Institute. His main contributions include the identification of the TGFβ receptors and signal transducers, and the central concept of how this pathway controls cell proliferation and differentiation. Recently, he defined genes and mechanisms for cancer cell dissemination and metastasis. Joan Massagué is an elected member of the U.S. National Academy of Sciences, the Institute of Medicine, and EMBO.
       Bart de Strooper (Dept of Mol. & Dev. Genetics, KU Leuven)
 
Bart.Destrooper@med.kuleuven.be
 
Bart de Strooper's research interests are the cell biology of Alzheimer's Disease and Parkinson's Disease. He demonstrated the central role of Presenilin in γ-Secretase processing of Amyloid Precursor Protein and Notch. He received several international prices including the Potamkin Prize in 2002, the Alois Alzheimer Award in 2004 and the Metlife Award in 2008.
EMBO Molecular Medicine
Meyerhofstrasse 1
D-69117 Heidelberg, Germany
Phone: +49 6221 8891 310
Fax: +49 6221 8891 240
info@embomolmed.org
 
ADVISORY EDITORIAL BOARD
Adriano Aguzzi, Zürich
Kari Alitalo, Helsinki
Stylianos Antonarakis, Geneva
Alan Ashworth, London
Hellmut Augustin, Heidelberg
Alberto Auricchio, Italy
Karen B. Avraham, Tel Aviv
Andrea Ballabio, Napoli
Yann Barrandon, Lausanne
Eduard Batlle, Barceona
Anton J. Berns, Amsterdam
Cédric Blanpain, Brussels
Clara D. Bloomfield, Columbus
Carlos Caldas, Cambridge
Vivian Cheung, Philadelphia
Kenneth Chien, Stockholm
Hans Clevers, Utrecht
Ralph DeBerardinis, Dallas
Elisabetta Dejana, Milano
Sven Diederichs, Freiburg
Oliver Eickelberg, Munich
Martin Eilers, Marburg
Marc Feldmann, London
Alain Fischer, Paris
Philippe Froguel, London
Gerardo Gamba, Mexico City
Bart Lambrecht, Ghent
Martin Gleave, Vancouver
Christian Haass, München
Carl-Henrik Heldin, Uppsala
Jan Hoeijmakers, Rotterdam
Nancy E. Hynes, Basel
Alain Israel, Paris
Barbara B. Kahn, Boston
Gerard Karsenty, New York
Cynthia Kenyon, San Francisco
Robert S. Kerbel, Toronto
Jean-Pierre Kinet, Boston
Andreas E. Kulozik, Heidelberg
Guido Kroemer, Paris
Claude Libert, Ghent
Salvador Moncada, London
Matthias Nahrendorf, Boston
Luigi Naldini, Milan
Mihai Netea, Nijmegen
Pierluigi Nicotera, Bonn
Bernd Nilius, Leuven
Eric N. Olson, Dallas
Stephen O'Rahilly, Cambridge
Albert Osterhaus, Rotterdam
Manolis Pasparakis, Köln
Christine Petit, Paris
Kornelia Polyak, Boston
Rino Rappuoli, Siena
Peter J. Ratcliffe, Oxford
Gideon Rechavi, Tel Aviv
Paola Ricciardi-Castagnoli, Singapore
Nadia Rosenthal, Monterotondo
Maria Rescigno, Milan
Owen Sansom, Glasgow
Nicholas J. Schork, La Jolla
Yosef Shiloh, Ramat Aviv
Gerald Shulman, New Haven
Bruce Spiegelman, Boston
Deepak Srivastava, San Francisco
Anu Suomalainen-Wartiovaara, Helsinki
Giulio Superti-Furga, Vienna
Elaine I. Tuomanen, Memphis
Axel Ullrich, Martinsried
Simon Wain-Hobson, Paris
Gerd Walz, Freiburg
Fiona Watt, London
Christian Weber, München
Lars Zender, Tuebingen
Massimo Zeviani, Cambridge